SARS-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020-May 2021
暂无分享,去创建一个
J. Scott | C. Agoti | P. Bejon | I. Adetifa | A. Ziraba | C. Bottomley | J. Mwangangi | E. Barasa | A. Agweyu | G. Warimwe | R. Aman | P. Bejon | A. Etyang | H. Karanja | D. Mugo | J. Nyagwange | J. Gitonga | J. Tuju | P. Wanjiku | A. Karani | E. Maitha | M. Otiende | A. Nyaguara | S. Voller | L. Ochola-Oyier | P. Amoth | M. Mwangangi | K. Kasera | W. Ng’ang’a | K. Gallagher | S. Uyoga | B. Tsofa | D. Akech | E. Gitau | E. Kagucia | R. Omore | D. Onyango | E. Barasa | D. Onyango | R. Aman | A. Sigilai | B. Karia | T. Misore | A. Ziraba | M. Ng’oda | B. Kutima | M. Toroitich | Evelyn Gitau | M. Ng'oda | Thomas Misore | Monica Toroitich | Abdhalah K Ziraba
[1] M. McMorrow,et al. Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 After the Second Wave in South Africa in Human Immunodeficiency Virus–Infected and Uninfected Persons: A Cross-Sectional Household Survey , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] J. Scott,et al. Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations , 2021, Journal of Clinical Virology.
[3] J. Scott,et al. Quantifying previous SARS-CoV-2 infection through mixture modelling of antibody levels , 2021, Nature Communications.
[4] M. Hoelscher,et al. Community SARS-CoV-2 seroprevalence before and after the second wave of SARS-CoV-2 infection in Harare, Zimbabwe , 2021, EClinicalMedicine.
[5] J. Hasenauer,et al. Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities , 2021, The Lancet Global Health.
[6] S. Tollman,et al. SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020–March 2021 , 2021, Emerging infectious diseases.
[7] M. Masika,et al. High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya , 2021, International Journal of Infectious Diseases.
[8] J. Scott,et al. Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021. , 2021, JAMA.
[9] P. Munywoki,et al. Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in Nairobi, Kenya, December 2020 , 2021, F1000Research.
[10] J. Scott,et al. Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya , 2021, Nature Communications.
[11] M. Keeling,et al. COVID-19 transmission dynamics underlying epidemic waves in Kenya , 2021, Science.
[12] J. Scott,et al. Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody Seroprevalence Among Truck Drivers and Assistants in Kenya , 2021, Open forum infectious diseases.
[13] J. Lessler,et al. Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 2020 , 2021, Emerging infectious diseases.
[14] J. Scott,et al. Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya , 2021, medRxiv.
[15] J. Scott,et al. Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in two Kenyan referral hospitals , 2021, medRxiv.
[16] J. Nkengasong,et al. The puzzle of the COVID-19 pandemic in Africa , 2020, Science.
[17] E. Hod,et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum , 2020, Nature Immunology.
[18] J. Scott,et al. Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors , 2020, Science.
[19] A. Gelman,et al. Bayesian Analysis of Tests with Unknown Specificity and Sensitivity , 2020, medRxiv.
[20] C. Cunningham-Rundles,et al. A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, Nature Medicine.
[21] S. Madhi,et al. Health and Demographic Surveillance Systems Within the Child Health and Mortality Prevention Surveillance Network , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] Blessing Mberu,et al. Health & Demographic Surveillance System Profile: The Nairobi Urban Health and Demographic Surveillance System (NUHDSS). , 2015, International journal of epidemiology.
[23] M. McMorrow,et al. Seroprevalence of SARS-CoV-2 after the Second Wave in South Africa in HIV-Infected and Uninfected Persons: A Cross-Sectional Household Survey, November 2020 – April 2021 , 2021, SSRN Electronic Journal.
[24] Kevin Marsh,et al. HEALTH AND DEMOGRAPHIC SURVEILLANCE SYSTEM PROFILE Profile: The Kilifi Health and Demographic Surveillance System (KHDSS) , 2012 .
[25] B. Gladen,et al. Estimating prevalence from the results of a screening test. , 1978, American journal of epidemiology.